Literature DB >> 11836173

Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil.

Fortunato Morabito, Massimo Mangiola, Caterina Stelitano, Silvia Deaglio, Vincenzo Callea, Fabio Malavasi.   

Abstract

CD38 expression by B-cell chronic lymphocytic leukemia (B-CLL) cells has been the focus of several recent studies. The aim of this study was to evaluate the prognostic impact of CD38 expression by peripheral blood lymphocytes on progression-free survival after first-line therapy with high-dose chlorambucil in 53 previously untreated patients affected by typical CD5+ CD23+ B-CLL.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11836173

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  4 in total

Review 1.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

Review 2.  CD38 in the pathogenesis of allergic airway disease: Potential therapeutic targets.

Authors:  Deepak A Deshpande; Alonso G P Guedes; Frances E Lund; Subbaya Subramanian; Timothy F Walseth; Mathur S Kannan
Journal:  Pharmacol Ther       Date:  2016-12-07       Impact factor: 12.310

3.  Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Alak Manna; Sonikpreet Aulakh; Prachi Jani; Salman Ahmed; Sharoon Akhtar; Marie Coignet; Michael Heckman; Zahara Meghji; Kirtipal Bhatia; Aarushi Sharma; Taimur Sher; Victoria Alegria; Fabio Malavasi; Eduardo N Chini; Asher Chanan-Khan; Sikander Ailawadhi; Aneel Paulus
Journal:  Clin Cancer Res       Date:  2019-04-02       Impact factor: 13.801

4.  The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Purinergic Signal       Date:  2006-05-30       Impact factor: 3.765
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.